Searched over 200M research papers
3 papers analyzed
These studies suggest that while serum ferritin radioimmunoassay is a powerful test for diagnosing iron-deficiency anemia, there are common analytical errors and biological variations in serum-based indicators, necessitating improvements in methodology and standardization.
18 papers analyzed
Serum ferritin (SF) is a widely used indicator for assessing iron status, particularly for diagnosing iron deficiency (ID). It is considered a powerful test with a high diagnostic accuracy, as evidenced by its area under the receiver operating characteristic curve of 0.95. However, SF levels can be influenced by inflammation, liver disease, and neoplastic conditions, which complicates its interpretation in these contexts . Despite these challenges, SF remains a cornerstone in iron status assessment due to its strong diagnostic capabilities.
Transferrin saturation and soluble transferrin receptor (sTfR) are additional serum-based indicators used to assess iron status. sTfR is particularly valuable as it is not an acute-phase reactant, making it less susceptible to the confounding effects of inflammation. However, the lack of assay standardization and common reference ranges for sTfR presents significant challenges in its interpretation. Transferrin saturation, while useful, also suffers from high biological and analytic variations, which can affect its reliability.
The Total Body Iron (TBI) model, which assesses the log ratio of sTfR to SF, has been adopted in recent years for a more comprehensive evaluation of iron status. This model covers the full spectrum of iron status and better predicts the absence of bone marrow iron compared to SF alone. The TBI model allows for continuous variable analysis, providing a more nuanced understanding of iron stores in the body.
Laboratory tests for iron status, including serum iron, iron-binding capacity, and erythrocyte protoporphyrin, exhibit significant analytic and biological variations. These variations can be particularly high for serum iron and iron-binding capacity, leading to inconsistencies between different laboratories. Understanding these sources of error is crucial for designing studies and interpreting results accurately.
Emerging research is exploring the potential of hepcidin, non-transferrin-bound iron, and reticulocyte indexes as indicators of iron status. These markers are still under investigation and are not yet widely adopted in clinical practice. Their future integration into iron status assessment could provide additional tools for more accurate diagnosis and management.
Interpreting iron laboratory results involves a multifaceted approach, utilizing various indicators such as serum ferritin, transferrin saturation, and soluble transferrin receptor. Each of these indicators has its strengths and limitations, influenced by factors like inflammation and assay standardization. The Total Body Iron model offers a more comprehensive assessment, while emerging markers like hepcidin hold promise for future advancements. Awareness of the analytic and biological variations in these tests is essential for accurate diagnosis and effective management of iron-related conditions.
Most relevant research papers on this topic